Frisch Janina, Rey-Rico Ana, Venkatesan Jagadeesh Kumar, Schmitt Gertrud, Madry Henning, Cucchiarini Magali
Center of Experimental Orthopaedics, Saarland University Medical Center, Homburg/Saar, Germany.
Department of Orthopaedic Surgery, Saarland University Medical Center, Homburg/Saar, Germany.
J Cell Mol Med. 2016 Mar;20(3):430-40. doi: 10.1111/jcmm.12774. Epub 2016 Jan 25.
Genetic modification of marrow concentrates may provide convenient approaches to enhance the chondrogenic differentiation processes and improve the repair capacities in sites of cartilage defects following administration in the lesions. Here, we provided clinically adapted recombinant adeno-associated virus (rAAV) vectors to human bone marrow aspirates to promote the expression of the potent transforming growth factor beta (TGF-β) as a means to regulate the biological and chondrogenic activities in the samples in vitro. Successful TGF-β gene transfer and expression via rAAV was reached relative to control (lacZ) treatment (from 511.1 to 16.1 pg rhTGF-β/mg total proteins after 21 days), allowing to durably enhance the levels of cell proliferation, matrix synthesis, and chondrogenic differentiation. Strikingly, in the conditions applied here, application of the candidate TGF-β vector was also capable of reducing the hypertrophic and osteogenic differentiation processes in the aspirates, showing the potential benefits of using this particular vector to directly modify marrow concentrates to generate single-step, effective approaches that aim at improving articular cartilage repair in vivo.
对骨髓浓缩物进行基因改造可能会提供便捷的方法,以增强软骨形成分化过程,并在损伤部位给药后提高软骨缺损部位的修复能力。在此,我们将临床适用的重组腺相关病毒(rAAV)载体应用于人类骨髓抽吸物,以促进强效转化生长因子β(TGF-β)的表达,作为在体外调节样本中生物学和软骨形成活性的一种手段。相对于对照(lacZ)处理,通过rAAV成功实现了TGF-β基因的转移和表达(21天后,从511.1 pg rhTGF-β/毫克总蛋白降至16.1 pg rhTGF-β/毫克总蛋白),从而能够持久提高细胞增殖、基质合成和软骨形成分化水平。引人注目的是,在此处应用的条件下,应用候选TGF-β载体还能够减少抽吸物中的肥大和成骨分化过程,这表明使用这种特定载体直接改造骨髓浓缩物以产生旨在改善体内关节软骨修复的单步有效方法具有潜在益处。